(SRT) Sartorius VZO O.N. - Ratings and Ratios

Sartorius Aktiengesellschaft is a global provider of bioprocess solutions and laboratory products and services, catering to the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The companys comprehensive portfolio includes bioreactors, fermenters, cell culture media, and various laboratory equipment and consumables, as well as services such as contract manufacturing, bioprocess consulting, and validation services.

The companys diverse product range is designed to support the development and production of biopharmaceuticals, cell and gene therapies, and other life science applications. Sartorius products and services are used by a wide range of customers, from research institutions to large biopharmaceutical manufacturers. With a history dating back to 1870, Sartorius has established itself as a trusted partner in the life science industry, with a strong presence in Europe, North America, and Asia.

From a technical analysis perspective, Sartorius stock has experienced a pullback from its 52-week high of €225.05, currently trading at €165.40. The stock is below its 20-day, 50-day, and 200-day simple moving averages (SMA), indicating a bearish trend. However, the average true range (ATR) of 3.83% suggests that the stock is not excessively volatile. Using the SMA20, SMA50, and SMA200 as reference points, a potential trading strategy could be to buy the stock if it breaks above the SMA20, with a target price of €178.66.

From a fundamental analysis perspective, Sartorius has a market capitalization of €13.7 billion and a forward price-to-earnings ratio of 38.61, indicating a relatively high valuation. However, the companys return on equity (RoE) of 4.61% is relatively low compared to its peers. Using the P/E Forward and RoE, a forecast for the companys future performance could be made. Assuming a stable RoE and a moderate growth rate, the stock could potentially reach a price of €200 within the next 12-18 months, representing a upside of around 21% from current levels.

Combining the technical and fundamental analysis, a potential investment thesis for Sartorius could be formed. The stocks current pullback and bearish trend could present a buying opportunity for investors with a medium-to-long-term horizon. However, investors should be cautious of the companys high valuation and relatively low RoE. A potential trading strategy could be to buy the stock if it breaks above the SMA20, with a target price of €178.66, and to monitor the companys future performance and adjust the investment thesis accordingly.